Welcome to LookChem.com Sign In|Join Free
  • or
METHYL 4-AMINO-2-FLUOROBENZOATE, with the molecular formula C8H8FNO2, is an ester derivative of benzoic acid that features a methyl group and an amino group. The incorporation of a fluorine atom in its structure classifies it as a fluorobenzoate, which may confer unique properties to the compound. This chemical compound is known for its versatility in various applications, particularly in the synthesis of pharmaceuticals and agrochemicals, as well as in organic chemistry for the preparation of other compounds. It has also garnered interest for its potential biological activities, such as its antifungal properties.

73792-08-2

Post Buying Request

73792-08-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

73792-08-2 Usage

Uses

Used in Pharmaceutical Synthesis:
METHYL 4-AMINO-2-FLUOROBENZOATE is used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with specific therapeutic properties.
Used in Agrochemical Production:
In the agrochemical industry, METHYL 4-AMINO-2-FLUOROBENZOATE is utilized as an intermediate, playing a crucial role in the creation of compounds that can protect crops and enhance agricultural productivity.
Used in Organic Chemistry:
METHYL 4-AMINO-2-FLUOROBENZOATE is employed as a reagent in organic chemistry for the preparation of other compounds, highlighting its importance in the synthesis of a wide range of chemical entities.
Used in Antifungal Applications:
METHYL 4-AMINO-2-FLUOROBENZOATE has been studied for its potential biological activities, particularly as an antifungal agent, which could be beneficial in treating fungal infections or in the development of antifungal products.

Check Digit Verification of cas no

The CAS Registry Mumber 73792-08-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,3,7,9 and 2 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 73792-08:
(7*7)+(6*3)+(5*7)+(4*9)+(3*2)+(2*0)+(1*8)=152
152 % 10 = 2
So 73792-08-2 is a valid CAS Registry Number.
InChI:InChI=1/C8H8FNO2/c1-12-8(11)6-3-2-5(10)4-7(6)9/h2-4H,10H2,1H3

73792-08-2 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Aldrich

  • (JWP00111)  4-Amino-2-fluoro-benzoic acid methyl ester  AldrichCPR

  • 73792-08-2

  • JWP00111-1G

  • 966.42CNY

  • Detail

73792-08-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name Methyl 4-Amino-2-Fluorobenzoate

1.2 Other means of identification

Product number -
Other names METHYL 4-AMINO-2-FLUOROBENZOATE

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:73792-08-2 SDS

73792-08-2Relevant academic research and scientific papers

DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST

-

Paragraph 0192-0194, (2020/07/07)

The present application belongs to the field of medicine. In particular, the present application relates to a diarylthiohydantoin compound as an androgen receptor antagonist or a pharmaceutically acceptable salt thereof, a preparation method of the same, a pharmaceutical composition comprising the compound, and a use thereof in treating a cell proliferative disease mediated by androgen. The compound of the present application has good antagonistic effect on androgen receptor and exhibits excellent antitumor effect.

INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR

-

Paragraph 0384-0385, (2019/06/07)

The present application discloses an indole as represented by formula (I) used as a CRTH2 inhibitor, and a pharmaceutically acceptable salt or tautomer of the indole, and an application of same in treating a disease related to a CRTH2 receptor.

Compound and composition as well as application thereof to drugs preparation

-

Paragraph 0109; 0112-0114, (2019/01/08)

The present invention relates to a compound having a structure of formula I or a pharmaceutically acceptable salt of the compound. Regarding the compound, R1 is selected from hydrogen, fluorine, and chlorine; R2 and R3 are independently selected from hydr

Mechanistic Evaluation of Bioorthogonal Decaging with trans-Cyclooctene: The Effect of Fluorine Substituents on Aryl Azide Reactivity and Decaging from the 1,2,3-Triazoline

Matikonda, Siddharth S.,Fairhall, Jessica M.,Fiedler, Franziska,Sanhajariya, Suchaya,Tucker, Robert A. J.,Hook, Sarah,Garden, Anna L.,Gamble, Allan B.

, p. 324 - 334 (2018/02/28)

Bioorthogonal prodrug activation/decaging strategies need to be selective, rapid and release the drug from the masking group upon activation. The rates of the 1,3-dipolar cycloaddition between a trans-cyclooctene (TCO) and a series of fluorine-substituted

As CRTH2 inhibitor of indole compounds (by machine translation)

-

Paragraph 0237; 0238; 0239, (2018/05/16)

The application discloses a formula (I) as shown in CRTH2 inhibitor of indole compound or its pharmaceutically acceptable salt, and their use in the treatment with the CRTH2 receptor-related diseases in the application. (by machine translation)

Design and synthesis of a potent, highly selective, orally bioavailable, retinoic acid receptor alpha agonist

Clarke, Earl,Jarvis, Christopher I.,Goncalves, Maria B.,Kalindjian, S. Barret,Adams, David R.,Brown, Jane T.,Shiers, Jason J.,Taddei, David M.A.,Ravier, Elodie,Barlow, Stephanie,Miller, Iain,Smith, Vanessa,Borthwick, Alan D.,Corcoran, Jonathan P.T.

supporting information, p. 798 - 814 (2018/01/01)

A ligand-based virtual screening exercise examining likely bioactive conformations of AM 580 (2) and AGN 193836 (3) was used to identify the novel, less lipophilic RARα agonist 4-(3,5-dichloro-4-ethoxybenzamido)benzoic acid 5, which has good selectivity over the RARβ and RARγ receptors. Analysis of the medicinal chemistry parameters of the 3,5-substituents of derivatives of template 5 enabled us to design a class of drug-like molecules with lower intrinsic clearance and higher oral bioavailability which led to the novel RARα agonist 4-(3-chloro-4-ethoxy-5-isopropoxybenzamido)-2-methylbenzoic acid 56 that has high RARα potency and excellent selectivity versus RARβ (2 orders of magnitude) and RARγ (4 orders of magnitude) at both the human and mouse RAR receptors with improved drug-like properties. This RARα specific agonist 56 has high oral bioavailability (>80%) in both mice and dogs with a good PK profile and was shown to be inactive in cytotoxicity and genotoxicity screens.

THIAZOLIDINONE COMPOUNDS AND USE THEREOF

-

Paragraph 0133-0134, (2017/09/21)

A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I): (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium.

SUBSTITUTED PYRAZOLYL-BASED CARBOXAMIDE AND UREA DERIVATIVES BEARING A PHENYL MOIETY SUBSTITUTED WITH A CO-CONTAINING GROUP AS VANILLOID RECEPTOR LIGANDS

-

Page/Page column 57; 59; 60; 61, (2013/05/23)

The invention relates to substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with a CO-containing group as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

THERAPEUTIC ARYL-AM I DO-ARYL COMPOUNDS AND THEIR USE

-

Page/Page column 76, (2011/04/14)

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-amido-aryl compounds of the following formula (for convenience, collectively referred to herein as "AAA compounds"), which, inter alia, a

OXADIAZOLE DERIVATIVES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS

-

Page/Page column 23-24, (2009/07/17)

The present invention relates to novel oxadiazole derivatives as nAChR agonists having pharmacological activity, processes for their preparation, compositions containing them and their use in the treatment of neurological, psychiatric disorders and gastro

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 73792-08-2